• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS
  • Email newsletter

Pharma industry news

Ebola treatment centre to be run by UK health charity

Ebola treatment centre in Sierra Leone to be run by UK health charity

Posted on: 22 November 2014 | Source: Doctors of the World UK

Doctors of the World UK is to run a 100-bed Ebola treatment centre in Sierra Leone that’s being custom-built in a town called Moyamba...

Boehringer Ingelheim

Nintedanib receives positive CHMP opinion in European Union for the treatment of IPF

Posted on: 21 November 2014 | Source: Boehringer Ingelheim

Boehringer Ingelheim today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for nintedanib (suggested brand name OFEV®) for the treatment of patients with idiopathic pulmonary fibrosis (IPF).

Stallergenes logo

STALLERGENES and ActoGeniX to develop an innovative new class of oral allergy treatments

Posted on: 21 November 2014 | Source: STALLERGENES / ActoGeniX

STALLERGENES exercised option to pursue the exclusive development of application of ActoGeniX’s technology for targeted delivery of allergen-based treatments...

GlobalData

Future bleak for Novartis’ Panobinostat in relapsed/refractory multiple myeloma, says GlobalData analyst

Posted on: 21 November 2014 | Source: GlobalData

The vote against the recommendation that the US Food and Drug Administration (FDA) approves Novartis’ panobinostat (Farydak) for use in relapsed/refractory multiple myeloma by the Oncologic Drugs Advisory Committee (ODAC) signals that a US marketing authorization is unlikely to be granted, according to an analyst with research and consulting firm GlobalData...

Cameron pledges £30 million for cutting-edge medical advances

Over £30 million committed across UK for cutting-edge medical advances

Posted on: 20 November 2014 | Source: Medical Research Council

Life-saving measures for patients have moved a step closer following the announcement by Prime Minister David Cameron of investments totalling over £30 million in emerging new treatments and technologies...

Moberg Pharma

Moberg Pharma appoints Jeff Vernimb as US General Manager

Posted on: 20 November 2014 | Source: Moberg Pharma

Moberg Pharma AB have appointed Jeff Vernimb as General Manager for its U.S. operations and a member of Moberg’s Management Team – effective from December 15, 2014...

Boehringer Ingelheim logo

Two new, large scale real-world analyses show fewer major bleeds and strokes with Pradaxa® than with warfarin

Posted on: 19 November 2014 | Source: Boehringer Ingelheim

Two new real-world data analyses presented at the American Heart Association’s Scientific Sessions 2014 independently demonstrate that routine treatment with Pradaxa® (dabigatran etexilate) was associated with fewer major bleeds and strokes compared to warfarin...

GlobalData

Despite patent cliffs, pharmaceutical market shows signs of stability, says GlobalData

Posted on: 19 November 2014 | Source: GlobalData

The pharmaceutical market is beginning to show signs of stability, with a review of 30 leading companies highlighting combined revenues of $718.7 billion in 2013, down just 0.2% from 2012, according to research and consulting firm GlobalData...

Boehringer Ingelheim logo

New data show dabigatran-specific antidote idarucizumab* restores blood clotting mechanism in humans

Posted on: 19 November 2014 | Source: Boehringer Ingelheim

New data on the investigational antidote idarucizumab show that it can reverse the effect of the oral anticoagulant Pradaxa® (dabigatran etexilate) on both blood coagulation and the blood clotting mechanism...

Amgen

Amgen presents long-term data showing efficacy and safety of investigational cholesterol-lowering medication evolocumab across lipid And LDL-C levels

Posted on: 19 November 2014 | Source: Amgen

Additional data analysis showed every two week and monthly dosing regimens of evolocumab were clinically equivalent...

Pills

Cost to develop and win marketing approval for a new drug is $2.6 billion, according to the Tufts Center for the Study of Drug Development

Posted on: 19 November 2014 | Source: The Tufts Center for the Study of Drug Development

Developing a new prescription medicine that gains marketing approval, a process often lasting longer than a decade, is estimated to cost $2,558 million, according to a new study by the Tufts Center for the Study of Drug Development...

MSD Logo

New data at ACR meeting show efficacy of Simponi® (golimumab) in treating patients with active non-radiographic axial spondyloarthritis

Posted on: 19 November 2014 | Source: MSD

Application for approval of new indication for golimumab has been filed with the European Medicines Agency...